Woburn-based biotech company ArQule Inc. has learned that partner Kyowa Hakko Kirin Co., Ltd., which has exclusive development rights to ArQule’s lead product candidate tivantinib in Japan, has suspended patient enrollment in its ongoing Phase 3 trial dubbed ATTENTION.